Welcome to our dedicated page for Respirerx Pharma news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on Respirerx Pharma stock.
Respirex Pharma (RSPI) delivers innovative therapeutic solutions through cutting-edge biopharmaceutical research. This news hub provides investors and industry professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company’s trajectory.
Access a centralized repository of press releases and verified news covering RSPI’s advancements in neurology, respiratory therapies, and translational medicine. Track critical updates including clinical trial progress, research partnerships, and peer-reviewed publication highlights that underscore the company’s scientific rigor.
Our curated collection ensures you stay informed about RSPI’s operational achievements without speculative commentary. Bookmark this page for efficient monitoring of earnings announcements, intellectual property developments, and collaborative ventures driving therapeutic innovation.
RespireRx Pharmaceuticals has issued a stockholder letter highlighting its 2024 progress and 2025 outlook. The company reported fourteen peer-reviewed publications in 2024, with two additional papers published in 2025. Their collaborator, Shirley Ryan AbilityLab, received a $1.8 million DoD grant for Phase 2A and 2B clinical trials testing CX1739 in spinal cord injured patients.
The company faces several challenges, including non-compliance with SEC reporting requirements, insufficient available common stock shares, and difficulties implementing the DoD grant. To address these issues, RespireRx has established two subsidiaries: ResolutionRx in Australia for cannabinoid program development, and EndeavourRx for neuromodulator programs.
The company has amended its preferred stock certificates to enable capital raising and is pursuing strategic collaborations, research partnerships, and grant opportunities. A high-scoring SBIR grant application for their GABAkines program is under review.
RespireRx Pharmaceuticals announced a $1.8 million award from the Department of Defense (DOD) to fund Phase 2 clinical trials for CX1739, their lead AMPAkine, aimed at improving bladder function in patients with spinal cord injury (SCI). Conducted by Shirley Ryan AbilityLab and led by Dr. Milap Sandhu, the study will have two stages: Phase 2A for single dose safety and efficacy, and Phase 2B for placebo-controlled trials. RespireRx has been allocated $252,200 for manufacturing and regulatory submissions. Clinical trials are projected to begin by Q4 2024. CX1739 has previously shown promising results in preclinical animal studies and early human trials.
FAQ
What is the current stock price of Respirerx Pharma (RSPI)?
What is the market cap of Respirerx Pharma (RSPI)?
